Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1.38	1.38	1.93	1.68	1.01
Revenue Growth (YoY)	-0.29%	-28.47%	14.79%	67.46%	-22.15%
Cost of Revenue	28.79	34.89	27.73	35.51	20.31
Gross Profit	-27.41	-33.51	-25.8	-33.83	-19.3
Selling, General & Admin	32.51	33	29.71	33.35	33.4
Operating Expenses	32.51	33	29.71	33.35	33.4
Operating Income	-59.91	-66.51	-55.51	-67.18	-52.7
Interest Expense	-8.7	-7.77	-5.24	-6.07	-5.01
Currency Exchange Gain (Loss)	4.92	-1.55	2.01	-3.3	-1.7
Other Non Operating Income (Expenses)	-0.57	-0.44	3.57	-25.79	238.7
EBT Excluding Unusual Items	-64.26	-76.27	-55.18	-102.34	179.29
Other Unusual Items	3.56	-7.51	-7.42	-2.69	-0.17
Pretax Income	-60.7	-83.78	-62.6	-105.03	179.13
Income Tax Expense	-0.54	-	-	-	-
Net Income	-60.16	-83.78	-62.6	-105.03	179.13
Preferred Dividends & Other Adjustments	1.32	1.41	1.77	-	-
Net Income to Common	-61.48	-85.19	-64.37	-105.03	179.13
Shares Outstanding (Basic)	1,457	1,242	1,119	1,016	874
Shares Outstanding (Diluted)	1,457	1,242	1,119	1,016	1,008
Shares Change (YoY)	17.26%	10.99%	10.17%	0.79%	38.99%
EPS (Basic)	-0.04	-0.07	-0.06	-0.10	0.21
EPS (Diluted)	-0.04	-0.07	-0.06	-0.10	-0.06
Free Cash Flow	-46.27	-58.03	-57.07	-55.68	-44.31
Free Cash Flow Per Share	-0.03	-0.05	-0.05	-0.06	-0.04
Operating Margin	-4347.90%	-4812.45%	-2873.09%	-3991.74%	-5243.98%
Profit Margin	-4461.32%	-6164.40%	-3331.94%	-6240.76%	17823.48%
Free Cash Flow Margin	-3357.55%	-4199.06%	-2954.14%	-3308.20%	-4409.35%
EBITDA	-57.85	-64.76	-53.98	-65.93	-52.38
D&A For EBITDA	2.06	1.74	1.53	1.25	0.32
EBIT	-59.91	-66.51	-55.51	-67.18	-52.7
Revenue as Reported	1.38	1.38	1.93	1.68	1.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.